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Background: Mortality rate among patients with stage five chronic kidney disease (CKD) maintained on hemodialysis
(HD) is high. Although evidence suggests that use of Vitamin D Receptor Activators (VDRA) in CKD patients increases
survival, few studies have examined the effect of VDRA in incident HD patients. The FARO-2 study evaluated the clinical
outcome of VDRA therapy on mortality in incident HD patients.
Methods: FARO-2 was a longitudinal epidemiological study performed on 568 incident HD patients followed
prospectively from 26 dialysis centers over a 3-year period. Data were collected every 6 months using a questionnaire,
obtaining clinical, biochemical and therapeutic parameters. Kaplan-Meier curves and Cox proportional hazard
regression models were used to determine cumulative probability of time-to-death and adjusted hazard ratios.
Results: 568 patients (68% male) with an average age of 65.5 years were followed up. Mean dialysis duration
at study entry was 3 months. VDRA use increased from 46% at 6 months to 54.7% at 36 months of follow-up
(p = 0.08). No difference was observed in the presence of comorbid diseases at baseline in patients with and
without VDRA therapy. Cumulative probability of survival at 24 months was 74.5% (95% CI: 70.2-78.3). Patients
receiving VDRA therapy showed a significant increase in survival at 24 months (80.7%; 95% CI: 75.7-84.8) compared to
those without (63.3%; 95% CI: 54.8-70.7, p <0.01). The presence of vascular disease, decreased hemoglobin,
increased P and lack of VDRA treatment were significantly associated with an increased risk of mortality. Lack of
VDRA treatment still remained significant as a predictor of mortality after adjusting for levels of PTH, P and Ca
(HR = 2.16, 95% CI: 1.09-4.30, p = 0.03).
Conclusions: Findings from FARO-2 indicate that in incident HD patients VDRA therapy was associated with
increased survival.
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Mortality rates among chronic kidney disease (CKD) pa-
tients undergoing hemodialysis (HD) is high and exceeds
those not undergoing HD [1,2]. The main cause of dialy-
sis related mortality has largely been attributed to
cardiovascular disease [2]. CKD patients are also affected
by mineral and bone disorders (CKD-MBD), resulting in* Correspondence: pmessa@policlinico.mi.it
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unless otherwise stated.abnormalities in serum calcium (Ca), phosphorous (P) and
parathyroid hormone (PTH). Changes in mineral metabol-
ism have also been associated with higher rates of both all-
cause and cardiovascular-related mortality [3-15]. The
majority of HD patients are also deficient in the endogen-
ous hormone, 1,25-dihydroxyvitamin D (calcitriol) [16].
The reduction in calcitriol levels, which are a well known
causal factor in the pathogenesis of secondary hyperpara-
thyroidism (SHPT) [17], has also been associated with the
poor clinical outcomes of these patients [18].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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other vitamin D metabolites may result in hypercalcaemia,
potentially contributing to increase the risk of morbidity
and mortality [19,20]. To overcome this problem, several
synthetic vitamin D receptor activators (VDRAs) have
been developed, that are less hypercalcemic and hyper-
phosphataemic and are efficacious in treating patients
with CKD-MBD, [21,22] and as such, are now considered
the standard therapy for patients with CKD [23]. In fact,
the occurrence of hypercalcemia and hyperphosphatemia
is more frequent during calcitriol treatment than with the
use of a selective VDRA (paricalcitol), possibly due to a
lesser bone resorption and intestinal absorption of these
metabolites [24,25]. This may translate into reduced risk
of vascular calcifications and hence cardiovascular events.
The use of VDRAs, such as calcitriol or the selective VDR
activator paricalcitol, is associated with improved survival
in HD patients [15,26-32]. It is also recognized that the
majority of these retrospective survival studies was per-
formed on prevalent chronic HD patients and it is known
that prolonged dialysis is an independent significant pre-
dictor of death [33]. To date, only few and small cohort
studies have examined the effect of VDRA therapy on
survival in incident HD patients. The original FARO study
was the first epidemiological study that evaluated SHPT
management and survival in HD patients in Italy [32,34].
The aim of the FARO-2 cohort, a sub-group of the
original FARO study, was to assess SHPT management
and alignment with K-DOQI target ranges, [35,36] and to
specifically evaluate the clinical outcome of VDRA
therapy on mortality in incident HD patients, using
time-dependent Cox models.
Methods
Study design
The FARO-2 study was a multicentric epidemiological
study performed on a subgroup of patients who initiated
the HD therapy over the course of the FARO study (con-
ducted between 2006 and 2007) [32,34]. FARO-2 was
undertaken in 26 dialysis centers in Italy. Data collection
was retrospective, involving the completion of another
two questionnaires for the year of 2008 (added to the
previous 4 questionnaires collected during FARO study
for the years 2006 and 2007). The physician attending
the dialysis procedure completed the clinical and labora-
tory parameter questions on the dedicated questionnaire
for each patient. Final data review and approval were
completed by the primary investigator at the study site.
Additional information on specific parameters included in
the survey has been previously described [34]. All subjects
who started dialysis treatment during the FARO study and
all subjects at the time of the 1st survey of the FARO
Study (April 2006) that had a dialysis vintage of ≤8 months
were included. Data are presented by semester from thebeginning of dialysis (irrespective of the moment in which
the patient entered into the FARO study). The follow up
period for each subject is variable and ranged from a mini-
mum of 6 months to a maximum of 3 years. All patients
provided written informed consent and the study was ap-
proved by all local Ethic Committees.
VDRA treatment
For patients with stage 5 CKD undergoing HD, the 2003
guidelines of the Kidney Disease Outcomes Quality Initia-
tive (KDOQI) of the National Kidney Foundation were
used [35]. According to these guidelines, target ranges for
these patients for iPTH concentrations were 150–300 pg/
mL and VDRA therapy was only administered to HD pa-
tients with iPTH >300 pg/ml. FARO2 was an observa-
tional study, therefore medication was administered at the
discretion of the treating physician, according to Italian
guidelines.
Statistical analysis
Descriptive statistics of categorical data are presented as
summary tables reporting frequencies and percentages,
while quantitative variables such as KDOQI parameters
were summarized using medians and interquartile
ranges. Comparisons between two groups of categorical
variables were analyzed by chi-squared tests. Differences
in the proportion of patients receiving VDRA therapy
over the study period were assessed by chi-squared for
trend. Differences for KDOQI parameters were evalu-
ated using Kruskal-Wallis test.
Risk of all-cause mortality was assessed standard sur-
vival techniques such as Kaplan-Meier curves to estimate
the cumulative probability of death. In particular, an ex-
tended Kaplan-Meier survival plot was also performed to
assess the effect of VDRA therapy (i.e., untreated vs. oral/
intravenous (IV) calcitriol or IV paricalcitol) on all-cause
mortality as previously described [15,32]. In brief, those
patients not receiving VDRA therapy for the entire follow-
up period were always considered as untreated; for those
who started VDRA therapy, the risk time for each patient
was divided into specific time contributions depending on
when treatment started. Before treatment started, the spe-
cific time contribution was for the untreated group. As
an-intention-to-treat analysis when a patient interrupted
or discontinued VDRA they were still considered in the
VDRA group. Two multiple time dependent Cox propor-
tional hazard regression models were performed to esti-
mate adjusted HRs (with 95% confidence intervals (95%
CI). The first model included various demographic and
clinical covariates, including age (per 10-year increase),
gender, comorbidities (i.e., hypertension: yes vs. no; dyslip-
idemia: yes vs. no; heart disease: yes vs. no; neoplasias: yes
vs. no; liver disease: yes vs. no; vascular disease: yes vs. no;
treatment of diabetes: yes vs. no; haemoglobin (per 1 g/dl
Table 2 Time-dependent characteristics in patients with
and without VDRA therapy
Characteristic Follow-up
time (months)
Total VDRA No VDRA p-value
Serum calcium
(mg/dl)
6 8.8 8.8 8.8 0.34
12 8.9 8.9 8.8 0.02
18 8.9 8.9 8.8 0.26
24 9.0 9.0 9.0 0.2
30 9.0 8.9 8.9 0.85
36 8.9 8.9 9.0 0.11
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(untreated vs. treated), calcium-based phosphate binder
use (no vs. yes) and non-calcium-based phosphate binder
use (no vs. yes). The second model, together with the pre-
viously described variables, also included the serum phos-
phorus (≤3.5 vs. >3.5 to 5.5; >5.5 vs. >3.5 to 5.5 mg/dL),
serum calcium (≤8.4 vs. >8.4 to 9.5; >9.5 to 10.5 vs. >8.4 to
9.5; >10.5 vs. >8.4 to 9.5 mg/dL), parathyroid hormone
[(PTH) ≤150 vs. 150 to 300; >300 vs 150 to 300 pg/ml].
All parameters were included as time changing variables
except age and gender. Patients who moved or were trans-
ferred to other dialysis centers or who were lost to follow-
up were censored as alive at the last visit performed. To
prevent possible non-proportionality of risks among clinical
centers, Cox proportional hazard regression models were
stratified by clinical center [37]. A p-value of <0.05 was con-
sidered statistically significant. Statistical analysis was per-
formed using SAS (version 9.2 for WindowsTM, Cary, NC)
and STATA (version 12.0, College Station, TX) software.
Results
Disposition and baseline clinical characteristics
Patient demographic and clinical characteristics are sum-
marized in Table 1. The proportion of males was higherTable 1 Baseline clinical characteristics in patients with
and without VDRA therapy
Clinical
characteristic
Total VDRA P-
valueYes No
General
N (%) 568 389 (68.5) 179 (31.5)
Gender (male),
n (%)
389 (68.5) 260 (66.9) 129 (72.1)
Median age
(IQR), years
70 (57–77) 69 (56–76.5) 70 (60–77) 0.31
Median height
(IQR), cn
165 (160–170) 165 (160–171) 167 (160–170) 0.89
BMI (Kg/M2) 23.5 (21.2-26.4) 23.5 (21.2-26.3) 23.4 (20.8-26.5) 0.47
Comorbid
diseases
Hypertension,
n (%)
496 (87.3) 347 (89.2) 149 (83.2) 0.05
Cardiovascular
disease, n (%)
338 (59.5) 233 (59.9) 105 (58.7) 0.78
Vascular disease,
n (%)
277 (48.8) 188 (48.3) 89 (49.7) 0.6
Diabetes, n (%) 164 (28.9) 109 (28) 55 (30.7) 0.52
Dyslipidemia,
n (%)
104 (18.3) 164 (42.2) 61 (34.1) 0.07
Liver disease,
n (%)
54 (9.5) 42 (10.8) 12 (6.7) 0.12
BMI = body mass index.
IQR = interquartile range.
Statistically significant p-values are highlighted in bold.(68.5%) than females (31.5%). At the start of dialysis, the
median age was 70 years for both women and men. The
frequency of dialysis sessions was 3 times per week for
83.1% of subjects, twice a week for 12.32% of subjects,
once a week for 4.05% of subjects. A small proportion of
subjects (0.18%) also had dialysis >3 times per week. Most
frequent comorbid diseases included hypertension (77%),
ventricular hypertrophy (55.3%) and cardiovascular dis-
ease (39.8%). Clinical characteristics remained the same
for patients receiving VDRA therapy compared to those
without VDRA therapy (Table 1). Furthermore, the pres-
ence of comorbid diseases at baseline was similar betweenSerum phosphorus
(mg/dl)
6 5.1 5.0 5.2 0.17
12 5.2 5.2 5.3 0.29
18 5.0 5.0 5.1 0.44
24 4.9 4.9 4.9 0.93
30 4.9 4.9 4.9 0.56
36 4.8 4.8 4.8 0.49
PTH (pg/ml) 6 225 313 157 <0.01
12 197 245 141.3 <0.01
18 201 227 155 <0.01
24 212 240.3 155 <0.01
30 247 268.3 148.5 <0.01
36 254 260 197.5 0.15
Serum albumin
(g/dl)
6 3.60 3.55 3.55 0.09
12 3.70 3.70 3.60 0.03
18 3.75 3.78 3.70 0.19
24 3.76 3.80 3.69 0.06
30 3.74 3.76 3.73 0.51
36 3.80 3.72 3.81 0.42
Hemoglobin (g/dl) 6 10.9 11.0 10.9 0.08
12 11.4 11.4 11.5 0.79
18 11.5 11.4 11.5 0.86
24 11.3 11.2 11.5 0.05
30 11.2 11.2 11.3 0.23
36 11.7 11.4 11.9 0.07
PTH = parathyroid hormone. P-values denote comparisons between VDRA and
no VDRA groups. Statistically significant p-values are highlighted in bold.
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70 years) and non-VDRA treated group (72.1% male; me-
dian age 70 years) (Table 1). Although a higher proportion
of VDRA-treated patients had hypertension (89.2 with
VDRA vs. 83.2 without VDRA, p = 0.05), this difference
was not deemed clinically significant. Of the 610 subjects
who were considered eligible for participation in the
FARO-2 study, 7 subjects were excluded because they were
referred to 2 centers that did not adhere to the project
while 35 were excluded because, on closer scrutiny, had a
dialysis start date earlier than 8 months of the date of study
enrollment, therefore not meeting the inclusion criteria.
The total sample size was 568 subjects. The number of
evaluable patients changed from the 1st survey (128 evalu-
able patients with a follow-up of 3 years) to the 6th survey
(568 evaluable patients with a follow-up of 6 months).Levels of PTH, Ca and P at baseline and follow-up
Levels of serum PTH (median values at 6 months vs
36 months; 225 vs 254 pg/ml), Ca (8.8 vs 8.9 g/dl) and P
(5.1 vs 4.8 mg/dl) for all patients did not differ significantly
from baseline (Table 2). Although median serum PTH
levels were significantly different in patients with VDRA
compared to those without VDRA therapy (approximately
40% higher in VDRA treated patients), no marked differ-
ence was observed for other biochemical (serum calciumTable 3 Concomitant therapy in patients over the follow-
up period
Follow-up time (months) Yes No
Treatment N % N %
VDRA 6 261 46 307 54.0
12 328 57.8 239 42.2
18 335 67.5 161 32.5
24 254 74.1 89 25.9
30 162 75.7 52 24.3
36 99 77.3 29 22.7
Non-calcium-based
phosphate binders
6 223 39.3 345 60.7
12 300 52.9 267 47.1
18 296 59.7 200 40.3
24 222 64.7 121 35.3
30 147 68.7 67 31.3
36 90 70.3 38 29.7
Calcium-based
phosphate binders
6 302 53.2 266 46.8
12 354 62.4 213 37.6
18 339 68.3 157 31.7
24 250 72.9 93 27.1
30 161 75.2 53 24.8
36 97 75.8 31 24.2and serum phosphorus) and laboratory parameters (serum
albumin and hemogobin) (Table 2).
Use of VDRA
389 (68.5%) patients received VDRA therapy at least once
during the follow up period and 191 (49.1%) were taken off
VDRA(even for a single visit). From the beginning of the
study, there was an increase in the use of VDRA from 46%
at 6 months to 54.7% at 36 months follow-up, although this
increase was not statistically significant (p = 0.08; Figure 1A)
(Table 3). Sub-analysis of patients who received VDRA
therapy revealed a significant decrease in the use of orally
administered calcitriol (68.5% at 6 month follow-up vs. 58%
at 36 month follow-up, p = 0.039) and, concomitantly, a sig-
nificant increase in the use of paricalcitol (IV) (20.9% at
6 months to 33.3% at 36 months, p = 0.045) was observed
between baseline and follow up (Figure 1B). Use of calcitriolFigure 1 Proportion of patients receiving VDRA therapy.
A) Proportion of patients receiving any form of VDRA. B) Proportion
of patients receiving the following various forms of VDRA: oral
calcitriol (hatched bars); intravenous paricalcitol (open bars) and
intravenous calcitriol (filled bars). Asterix denote statistical significance
between 6 and 36 month time points where * = p < 0.05.
Messa et al. BMC Nephrology  (2015) 16:11 Page 5 of 8(IV) was only in a small proportion of patients (<10%) and
did not change over the study period (Figure 1B).
Concomitant medication
In addition to VDRA use, patients received concomitant
medication. At baseline the majority of patients (~70%)
received iron supplementation, followed by calcium car-
bonate (~50%), other phosphate binders (~30%) and
insulin (~20%). The proportion of patients receiving
medication changed over the study period (Table 3). The
proportion of patients receiving non-calcium-based
phosphate binders and calcium-based phosphate binders
increased from 39.3% at 6 months to 70.3% at 36 monthsFigure 2 Kaplan Meier plots showing survival rate of all patients. The
for at least 2 years is 74.5% (95% CI: 70.2-78.3). Dotted lines represent uppe
mortality) for FARO-2 patients and B) Kaplan Meier plot showing effect of VDRA oand 53.2% at 6 months to 75.8% at 36 months respect-
ively (Table 3). While the proportion of patients receiv-
ing the phosphate binder sevelamer HCl (25.2% vs
38.3%, p = 0.0039), calcium acetate (3.7% vs 10.2%,
p = 0.0046) or the calcimimetic cinacalcet (0.9% to 9.4%,
p < 0.0001) significantly increased from 6 months to
36 months, the use of iron supplements (73.9% vs 64.8%,
p = 0.049) or calcium carbonate (47.4% vs 39.8%, p = 0.15)
decreased from 6 months to 36 months.
Cause of mortality
In this survey, approximately one quarter (25.2%) of
patients died. At 12 months, 47 subjects died (8.3%), atprobability of surviving at least 1 year is 88.6% (95% CI: 85.6-91.0), and
r and lower 95% confidence intervals. A) Survival estimates (all cause
n survival. Probability of survival at 2 years is indicated. HD=hemodialysis.
Table 5 Hazard ratios of time to death (any cause)
HR 95% CI p-value
Age (per 10 year increase) 1.35 0.98 1.86 0.06
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died, at 30 months 25 (24%) died and at 36 months 7
(25.2%) died.The main cause of death was heart failure
25.9% (n = 37), followed by other unspecified causes
(17.5%), vascular causes and neoplasia (both 16.1%),
cachexia (15.4%) and sepsis (9.1%). The cumulative
probability of survival (all-cause mortality) from start of
dialysis is presented in Figure 2A. Kaplan-Meier analysis
revealed that the cumulative probability of surviving at
least 12 months was 88.6% (95% CI: 85.6-91.0), at least
24 months was 74.5% (95% CI: 70.2-78.3) (Figure 2A).
Effect of VDRA on survival
Patients who received VDRA therapy showed a signifi-
cant higher survival at 24 months (80.7%; 95% CI: 75.7-
84.8) compared to those without VDRA treatment
(63.3%; 95% CI: 54.8-70.7) (Figure 2B). Actually, the ef-
fect of VDRA treatment reveals that the event curves
had already separated by 6 months and continued to di-
verge up to 2 years (Figure 2B).
Effect of demographic and clinical variables on survival
Cox proportional hazard regression models were used to
estimate time to all-cause mortality hazard ratios (HR).
The presence of hypertension, vascular disease, decreased
hemoglobin and lack of VDRA treatment were significantly
associated with an increased risk of mortality (Table 4).Table 4 Hazard ratios of time to death (any cause),
without PTH, Ca and P
HR 95% CI p-value
Age (per 10 year increase) 1.33 0.99 1.80 0.06
Gender (male vs female) 1.22 0.63 2.36 0.55
History of hypertension (yes vs no) 0.32 0.10 0.98 0.05
History of dyslipidemia (yes vs no) 0.94 0.42 2.09 0.88
Heart disease (yes vs no) 1.62 0.73 3.58 0.24
Neoplasias (yes vs no) 2.15 0.93 5.00 0.07
Liver disease (yes vs no) 2.04 0.77 5.41 0.15
Vascular disease (yes vs no) 4.60 2.04 10.38 0.00
Treatment of diabetes (yes vs no) 1.61 0.71 3.61 0.25
Hemoglobin (per 1 g/dl increase) 0.64 0.49 0.84 0.00
Albumin (per 1 g/dl increase) 1.12 0.87 1.45 0.38
VDRA (no vs yes) 2.69 1.38 5.22 0.00
Ca-based PiB (no vs yes) 1.11 0.47 2.67 0.81
NoCa-based PiB (no vs yes) 0.58 0.27 1.22 0.15
Data presented as hazard ratios (HR) and upper and lower 95% confidence
intervals (CI).
PTH = parathyroid hormone; P = phosphorous, Ca = calcium; VDRA = vitamin D
receptor activator; Ca-based PiB = calcium containing phosphate binders;
noCa-based PiB = non calcium containing phosphate binders. All variables
(but age and gender) were included as time dependent covariates. Statistically
significant p-values are highlighted in bold.Additional analysis adjusted for levels of the biochem-
ical parameters PTH, P and Ca showed that lack of
treatment with VDRA still remained significant as a
predictor of mortality (HR = 2.16, 95% CI: 1.09-4.30,
p = 0.03) (Table 5).
Discussion
The main finding of this analysis of the subgroup of the
FARO cohort shows that VDRA treatment in incident
HD patients (FARO-2 cohort) is associated with reduced
overall mortality. This benefit was maintained even after
adjusting for levels of the biochemical parameters PTH,
P and Ca.
Previous studies have consistently shown benefit in
reducing overall and CV-related mortality following VDRA
use, compared to non VDRA use, [9,26-32] although
studies comparing efficacy of different VDRA molecules
(for example paricalcitol compared to calcitriol) on survival
outcome have shown differing results [30,38,39].
What makes the FARO-2 study unique is the fact that
we have examined the effect of VDRA therapy on sur-
vival in incident HD patients, the first study of this kindGender (male vs female) 1.12 0.57 2.21 0.75
History of hypertension (yes vs no) 0.33 0.10 1.07 0.07
History Dyslipidemia (yes vs no) 1.03 0.43 2.45 0.95
Heart disease (yes vs no) 1.38 0.60 3.16 0.45
Neoplasias (yes vs no) 1.89 0.77 4.63 0.16
Liver disease (yes vs no) 1.87 0.64 5.45 0.25
Vascular disease (yes vs no) 4.32 1.90 9.80 0.00
Treatment of diabetes (yes vs no) 1.72 0.74 4.01 0.21
Hemoglobin (per 1 g/dl increase) 0.61 0.46 0.81 0.00
Albumin (per 1 g/dl increase) 1.08 0.85 1.38 0.54
PTH≤ 150 vs 150 < PTH≤ 300 pg/ml 1.02 0.47 2.24 0.96
300 > PTH vs 150 < PTH≤ 300 pg/ml 0.55 0.19 1.57 0.26
P≤ 3.5 vs 3.5 < P≤ 5.5 mg/dl 2.16 0.89 5.26 0.09
P > 5.5 vs 3.5 < P≤ 5.5 mg/dl 2.63 1.23 5.60 0.01
Ca≤ 8.4 vs 8.4 < Ca≤ 9.5 mg/dl 1.88 0.90 3.92 0.09
Ca > 9.5 vs 8.4 < Ca≤ 9.5 mg/dl 1.27 0.44 3.71 0.66
VDRA (no vs yes) 2.16 1.09 4.30 0.03
Ca-based PiB (no vs yes) 1.15 0.46 2.89 0.77
NoCa-based PiB (no vs yes) 0.70 0.31 1.58 0.39
Data are presented as hazard ratios (HR) and upper and lower 95% confidence
intervals (CI). PTH = parathyroid hormone; P = phosphorous, Ca = calcium;
VDRA = vitamin D receptor activator; Ca-based PiB = calcium containing
phosphate binders; noCa-based PiB = non calcium containing phosphate
binders. All variables (but age and gender) were included as time-dependent
covariates. Statistically significant p-values are highlighted in bold.
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cause of death in these patients is attributed to CV-
related events [1,2] and that VDRA use may play a
beneficial effect on survival in HD patients [9,15,26-32].
In fact, as previously observed in the FARO study, [32]
in the present analysis we have also noted that the pres-
ence of vascular disease was a significant predictor of
mortality. In line with these data, vascular-related co-
morbidities have previously been linked to increased
morbidity and mortality in HD patients [40,41]. There is
no clear explanation on the precise mechanisms by
which VDRA therapy might provide its cardio-vascular
protective effects. To address this, the PRIMO study, a
multinational double-blind randomized placebo-
controlled trial, examined the effect of paricalcitol (2 μg
daily) using cardiac endpoints as measures of CV struc-
ture and function (e.g. left ventricular mass) [42]. Al-
though findings from this trial did not demonstrate any
effect of paricalcitol on left ventricular mass or improved
measures of diastolic function over 48 weeks, this study
did show that paricalcitol use was associated with fewer
CV-related hospitalizations, with an attenuated rise in BNP
levels and decreased left atrial volume [42,43].
Collectively, these findings suggest a possible cardio-
vascular protective effect of VDRA and in particular of
paricalcitol, though the exact mechanisms of this effect
still need to be fully elucidated.Study limitations
There are, however, some limitations of the FARO-2
study that need to be addressed. Although the number
of patients at baseline was relatively large (n = 568), a
larger sample size would have permitted additional sub-
analysis, accounting for drop-outs and death. The small
sample size also precluded the possibility of evaluating
the possibility of any potential dose-related effect of
VDRA therapy on overall survival. In addition, although
some classical factors did not attain statistical signi-
ficance, possibly again attributed to the low sample
number, several other clinical characteristics emerged as
risk factors for survival, corroborating other studies
[32,40,41]. Furthermore it was retrospective and obser-
vational design. On the other hand, there are several
strengths of the FARO-2 study worth noting. First, it is
based on an observation over a long period of time
(36 months) of incident CKD patients undergoing dialy-
sis treatment. Second, it was a multicentric study with
the contribution of many centers distributed around
Italy and therefore, its findings can be considered well
representative of the entire Italian dialysis population.
Furthermore, no studies are available reporting on the
effect of VDRA therapy on mortality data on incident
HD Italian population.Conclusions
In summary, the present study suggests that VDRAs
may play an important role in decreasing all-cause and
cardiovascular mortality in incident HD patients. How-
ever, considering the inherent limitations of retrospect-
ive analyses, the benefit of VDRA treatment on survival
in HD patients still remains to be confirmed in large
prospective randomized clinical trials.Competing interests
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